ANI Pharmaceuticals
ANIP
146 hedge funds and large institutions have $337M invested in ANI Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 65 increasing their positions, 28 reducing their positions, and 23 closing their positions.
132% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 28
10% more capital invested
Capital invested by funds: $305M → $337M (+$31.5M)
0.72% less ownership
Funds ownership: 55.82% → 55.1% (-0.72%)
3% less funds holding
Funds holding: 151 → 146 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
88% less call options, than puts
Call options by funds: $1.72M | Put options by funds: $14M
Top Buyers
| 1 |
BlackRock
New York
|
+$5.61M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$5.32M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$4.6M |
| 4 |
JP Morgan Chase
New York
|
+$4.48M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.08M |
Top Sellers
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$19.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$5.87M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.68M |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$3.35M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.68M |
ANIP Hedge Fund Activity: Q3 2017 in Review
146 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2017, worth a combined $337M — up 10% from $305M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ANIP and 18 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 65 added.
The largest buyer was BlackRock, adding an estimated $5.61M. The largest seller was Glenmede Trust, exiting entirely with an estimated $19.7M sold.
- 146 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2017, down from 151 in Q2 2017.
- Funds reported $337M of ANI Pharmaceuticals stock for Q3 2017, up 10% quarter-over-quarter.
- 18 funds opened new ANI Pharmaceuticals positions in Q3 2017 and 23 closed out, a net change of -5 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2017 was BlackRock, an estimated $5.61M added.
- The largest ANI Pharmaceuticals seller in Q3 2017 was Glenmede Trust, an estimated $19.7M sold.
Based on aggregated 13F filings for Q3 2017.